EANS-Adhoc: SYGNIS Pharma AG SYGNIS Announces Prolongation of Standby Equity
Distribution Agreement
--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
31.07.2012
Ad hoc-Release according to § 15 WpHG
SYGNIS Announces Prolongation of Standby Equity Distribution Agreement
Heidelberg, July 31, 2012 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN
DE000A1E9B74; Prime Standard) has ahead of schedule agreed a prolongation of
the standby equity distribution agreement (SEDA) with YA Global Master SPV LTD
(YA Global) effective from November 1, 2012 for further three years with
unchanged conditions. The agreement provides SYGNIS Pharma AG with the option
to request YA Global, during the term of the agreement, to subscribe for newly
issued SYGNIS shares from the Company's authorized capital in tranches of up to
EUR 500,000 each. The subscription price of the new shares will be determined
at 95% of the lowest volume-weighted average price of one of the five trading
days following the date of the relevant draw down notice.
The total value of this equity facility aggregates to up to EUR 10
million, provided that the aggregate number of shares issued to YA Global
shall not exceed 9,9% of SYGNIS Pharma AG's share capital. YA Global
can either accumulate these shares or place them in the market. However, YA
Global is committed not to short sell or enter into any hedging transactions
related to the particular company stock.
The prolongation is subject to the condition precedent that the German Federal
Financial Supervisory Authority (Bundesanstalt für
Finanzdienstleistungsaufsicht) grants an exemption from the obligations
pursuant to sec.35 of the German Takeover Act (Wertpapiererwerbs- und
Übernahmegesetz)toGenetrix, A.B., and parties affiliated or acting in concert
with Genetrix, A.B., regarding the proposed contribution of X-Pol into SYGNIS
Pharma AG in particular to submit a mandatory tender offer to the existing
shareholders of SYGNIS Pharma AG in connection with the related capital
increase of SYGNIS Pharma AG.
**** end of ad hoc ****
For further information please contact:
|SYGNIS Pharma AG | |
| |
|Peter Willinger | |
| |
|Tel: +49 6221 454 836 | |
| |
|Email: peter.willinger@sygnis.de | |
| |
### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and
imponderability and can be affected by other factors as a consequence of which
the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly
from the established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise these
statements in the light of new information or future results or for any other
reason.
###
Further inquiry note:
Marc Risch
Telefon: +49 (6221) 454 - 737
E-Mail: Marc.Risch@sygnis.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English